Compare Global X Cloud Computing ETF (CLOU) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Cloud Computing ETF vs ResMed Inc. — how do they compare? Global X Cloud Computing ETF trades at $27.67, while ResMed Inc. trades at $226.99 (market cap $32.78B). The key difference: ResMed Inc. pays a 1.17% dividend while Global X Cloud Computing ETF pays none, and Global X Cloud Computing ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| CLOU | RMD | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $28.09 | $293.73 |
52-Week Low | $17.60 | $182.82 |
Market Cap | — | $32.78B |
Enterprise Value | — | $32.14B |
Dividend Yield | — | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CLOU, the Global X Cloud Computing ETF, trades at $27.77, down 1.14% today, with technical indicators showing a bullish trend from moving averages but overbought signals from RSI levels above 83. The ETF offers diversified exposure to cloud computing stocks like Snowflake and Datadog, benefiting from long-term growth drivers in digital transformation.
The outlook remains positive due to strong non-AI growth factors and resilient subscription revenues, though risks include sector volatility and competitive pressures. Analyst sentiment is bullish, with buy ratings highlighting growth potential beyond short-term hype.
ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.
Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Cloud Computing ETF
CLOU is a thematic ETF that invests in companies leading the cloud revolution. It targets providers of SaaS, PaaS, and IaaS, including major firms like Salesforce, Akamai, and Shopify that drive modern digital infrastructure.
Read more on CLOU →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
